Answers are grounded in this paper and cite their sources.
Therapies for visceral diseases have advanced more rapidly than the routes used to deliver them. Oral dosing is limited by degradation and first-pass metabolism; repeated injections impose practical burdens; and surgery-based local delivery is restricted to perioperative settings. Microneedle patches provide a potential platform that can be deployed at two distinct interfaces: organ-surface delivery for local treatment and transdermal delivery through the skin for systemic exposure. Existing reviews have mainly focused on microneedle materials, dermatological applications, or individual organ systems. This review compares skin-applied and organ-surface microneedle delivery within one framework, with emphasis on release design, cargo constraints, microvascular targets, and translational requirements. Organ-surface patches have shown therapeutic efficacy in preclinical cardiac and hepatic models. Skin-applied patches have also produced remote organ effects in selected preclinical models, but most studies do not quantify target-organ exposure, and large-animal or human pharmacokinetic evidence remains limited. We therefore distinguish patch release, systemic absorption, target-organ exposure, and therapeutic efficacy as separate levels of evidence. We further discuss challenges related to peptide, protein, and extracellular-vesicle stability, dose capacity, scalable manufacturing, and regulation. Clarifying these gaps may help guide the development of microneedle patches for visceral diseases.
No takes yet. Share an insight, caveat, or question.
Teng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: